Careers in Discovery is your window into the world of Pharma & Biotech. Featuring interviews each week with leaders in Drug Discovery and R&D, you’ll learn about the careers of these influential figures, the work they are doing, how they got to where they are and what advice they’d give their younger selves. Brought to you by Singular: Building Brilliant Biotechs. Connect with us at: LinkedIn: https://www.linkedin.com/company/singular-biotech/ www.singular-biotech.com
…
continue reading
I’m on a mission to meet as many of the world’s best CEOs as I can. I want to understand what makes them tick, what great leadership looks like from their perspective, and how they learned to be great at what they do. This started out as a solo quest, but quickly I realised I should share these conversations with the world. If you’re a CEO right now who wants to be more effective in your work, or if you have aspirations to take the top job, then CEO Sessions is the right place to be. Come an ...
…
continue reading
Biotech, TechBio and Life Science investors can seem a mysterious crew to those who encounter them - come behind the curtain and learn about the view from their side of the negotiating table. Tom Froggatt, CEO of Singular, shares his conversations with angel investors, VCs and others who are active in the human health sector, as they discuss the fundraising market, how they assess investments, the mistakes they see and their advice for those heading out to raise money to save the lives of pa ...
…
continue reading
Welcome to another episode of CEO Sessions! This week we’re joined by Tony de Fougerolles, a CEO with a fascinating journey through the biotech world. Tony's been at the helm of several companies, sits on multiple boards, and has seen the role of a CEO from many different angles - from securing funding, to building strong company cultures and navig…
…
continue reading
In this week’s episode of Careers in Discovery, we sit down with Marcin Paduch, Head of Platform Biology at Metaphore Biotechnologies. Marcin shares his insight into the exciting work happening at Metaphore, where they’re using the power of biomimicry and machine learning to develop new therapeutics. He explains how their MIMIC platform helps tackl…
…
continue reading
In the very first episode of CEO Sessions, I’m joined by Emma Banks, CEO of ramarketing. We explore the realities of leading a company today, from the challenges of hybrid work to staying true to yourself as a leader. Emma shares her experiences in the pharma industry, the impact of leadership programs like Vistage, and the lessons she’s learned wh…
…
continue reading
In this latest episode of Careers in Discovery, we sit down with Alistair Henry, the new Chief Scientific Officer at UCB, to talk about his remarkable 26-year journey with the company. Alistair shares his passion for science and how it led him from a curious teenager to a leader in drug discovery, working on ground-breaking projects in immunology a…
…
continue reading
This week on Careers in Discovery, we're delighted to be joined by Kenny Duncan, SVP of Chemistry at Accent Therapeutics, where we explore the evolving landscape of drug discovery and the critical role chemistry plays in advancing new therapies. Kenny takes us through his incredible career journey, from his early passion for chemistry to becoming a…
…
continue reading
Could AI be the key to reducing the high failure rate in drug discovery? This week on Careers in Discovery, we explore this critical question with Richard Law, Chief Business Officer at Exscientia, who has been at the forefront of integrating AI into the Biotech industry for decades. Richard shares his fascinating career journey, from his early day…
…
continue reading
This week I’m joined by Hazel Jones, CEO of Enhanc3d Genomics. Hazel shares her journey from her early days in Biotech to leading a company at the cutting edge of 3D genomics. We explored Hazel's career path, her transition into a CEO role and her insights on leadership, the significance of networking, and balancing professional and personal life.…
…
continue reading
This week on Careers in Discovery, we are joined by Peter Pack, an influential figure in the biotechnology industry with a career spanning over two decades. Peter's journey has taken him from Germany to the dynamic biotech landscape of the UK, where he now operates as a strategic partner and advisor to private equity firms and startups. In our conv…
…
continue reading
On this episode, I chat with Jason Mellad, CEO of Start Codon, about the Biotech investment market and startup success. Jason talked about the importance of strong, adaptable teams in early-stage companies and offers plenty of practical advice on understanding the market, recognising weaknesses, and trying to continuously improve. He shared the mos…
…
continue reading
"Science and technology have always fascinated me, and I've always been one to challenge the status quo." This week on Careers in Discovery, we welcome Jose Munoz-Olaya, Chief Scientific Officer of Valink Therapeutics. Jose shares his journey from an eager intern to a leader in biotechnology, emphasizing the importance of mentorship and the power o…
…
continue reading
Mike Stubbington and CS Genetics are on a mission to democratise single cell genomics. We caught up with Mike recently and discussed what being kind really looks like as a scientist, why you should move on when the time is right, and a whole lot more.Di Tom Froggatt
…
continue reading
We first interviewed Ben Cross five years ago, when he was the Head of Functional Genomics at Horizon Discovery, and we're delighted to welcome him back to the podcast as CTO of PhoreMost, an innovative target discovery company focused on drugging the undruggable. Ben caught us up on what he's learned over the last five years, including why failing…
…
continue reading
Shane Hegarty is the Chief Scientific Officer of Axonis Therapeutics, a Boston-based Biotech targeting KCC2 to revive neurons and treat people suffering from neurological disorders. Shane shared with us the story of his transition from academic to Biotech entrepreneur, why communication, persistence, collaboration and focus are critical skills for …
…
continue reading
Maude Tessier is the Chief Business Officer at Seismic Therapeutic, the machine learning immunology company building a discovery platform centred on parallel drug development. Maude joined us on Careers in Discovery to talk about the impact of machine learning on drug development, taking control of her career by literally knocking on doors, balanci…
…
continue reading
Vern de Biasi is VP of Business Development at BenevolentAI, one of the world's leaders in the application of cutting edge technology to drug discovery. Vern's career has seen him travel the world, from the UK to Italy, China and the US, and he shared with us the key lessons he's learned along the way.…
…
continue reading
Jordan Lane is the Chief Scientific Officer of Ignota Labs, a company leveraging AI to rescue failed drug programmes. Jordan joined us to talk about building conviction, seeking feedback & maintaining networks, the huge opportunity lying in failed research, and why risk is relative in your career.Di Tom Froggatt
…
continue reading
Before we launch into CEO Sessions fully, I wanted to share a little about why I'm doing this podcast and what we're trying to achieve with it. Come along and join the Session, and I'll tell you a bit about my journey as a CEO so far, as well as where I think we're heading.Di Tom Froggatt
…
continue reading
Pam Garside is an experienced angel investor and Chair of Cambridge Angels, one of the UK's leading investor networks. On this epsiode of The Other Side of The Table, we sat down with Pam to discuss the importance of smart money, why tenacity, boldness and perserverance are critical traits for founders, and her top tips on your investment deck. Enj…
…
continue reading
Bill Eldridge is an experienced scientific and commercial leader, one of the founding team members of the VHH antibody company Isogenica, and now their CEO. Bill joined us to talk about his career, the huge potential that still exists within antibody discovery and the magic of seeing a 96 well ELISA plate turn blue after months of failure! Enjoy...…
…
continue reading
We're back on The Other Side of the Table with Lee Lindley, Investment Manager at Mercia Ventures. Lee and I got into a range of topics in this podcast, including the importance of engaging early with investors, thinking beyond your next round and why it's so critical for CEOs to get their team involved in fundraising conversations. Join us for all…
…
continue reading
Namir Hassan is the CEO of Zelluna Immunotherapy, a cancer cell therapy company harnessing natural immunity to treat solid tumours. Namir joined us on Careers in Discovery to talk about when precision medicine gets too precise, the importance of servant leadership and trusting the journey in your career. Enjoy!…
…
continue reading
Hanadi Jabado is the Managing Partner at Sana Capital, a fund with a brilliant mission - to heal the world. Hanadi talked to us on The Other Side of The Table about the investment philosophy behind that mission, why algorithms aren't really what matters, the key role that trust plays in effective founder-investor relationships and why the market ma…
…
continue reading
Now a Non-Executive at a range of leading Biotech companies including Spirea, PharmEnable, Macomics, NanoSyrinx and Elasmogen, Jane Dancer has built a highly successful career in Business Development in the sector. Jane joined us to discuss that career, how she created a portfolio of NED positions, the real value of an MBA and whether you really ne…
…
continue reading
Come join me and the ever-insightful Darrin Disley, founding CEO of Horizon Discovery, current Chief Exec of Mogrify and investor in more than 40 Life Sciences and Social Enterprise businesses. In this episode, we got into why angel investors have different motivations, the importance of vision, why getting your cap structure right is absolutely cr…
…
continue reading
I'm back on The Other Side of The Table with Sean Kendall, Partner at ARCH Venture Partners. We're talking his view on the market (including my favourite quote of the series so far - "it's hard to fall out of the basement window"), why everything starts with high quality science, and how to tell if a market is "big enough" for investors.…
…
continue reading
This time around I'm with Mark Wyatt, Investment Director at Northern Gritstone, a group focused on realising the potential of innovation from universities across the North of England. In this episode, you'll hear about the importance of purpose to investors, what the due diligence process is really about and why you shouldn't be afraid to show the…
…
continue reading
This time around on The Other Side of The Table, come with me to meet Uzma Choudry, Biotech/TechBio investment lead at Octopus Ventures. Uzma built Octopus' TechBio desk and is an active investor and board member at several Biotech and TechBio companies - if you've spent any time on the UK Bio networking scene, you may well have come across her. Th…
…
continue reading
Next up on The Other Side of The Table, I'm joined by Gian Seehra. Gian founded two successful Biotech companies, raising c. $16m along the way, before heading into the world of VC. During his time at QVentures and Octopus Ventures, he invested into Healthtech and Life Sciences companies, and now runs a business helping Seed to Series B founders se…
…
continue reading
On this first episode of The Other Side of the Table, I'm with Jason Foster. Jason is a seasoned entrepreneur, investor and Biotech CEO with an amazing track record on both sides of the funding table, including a very impressive $100m Series B with his current company, Ori Biotech. His insight into the drivers of the current fundraising climate and…
…
continue reading
"I see all the other element of my current role - the leadership, management and mentoring - as enabling the science." Samantha Bailey-Bucktrout is the Senior Vice President of Research at Akamis Bio, a company harnessing the power of tumour gene therapy in the fight against cancer. Samantha talked to us about her career in cancer immunotherapy, wh…
…
continue reading
"You can learn corporate finance. You can do Excel modelling. You can read books on negotiation. But I strongly believe that Business Development is an art, and it's something that you can only really learn by doing." Beverley Carr is the Chief Business & Operating Officer of Amphista Therapeutics, a company re-engineering TPD therapies to tackle c…
…
continue reading
"I realised that drug development was much more than just research. There's a huge amount of work beyond coming up with a molecule, but research scientists just don't get exposed to it." Janette Thomas has built a career from Researcher to Project Manager, Operations Director and now CEO of Five Alarm Bio, a company focused on novel approaches to a…
…
continue reading
"If you've got into science because science itself motivates you, try and stay with it. Do other things too, learn what you need to, but be careful not to leave that science behind." Dan Williams is the CEO of SynaptixBio, a company dedicated to developing lifesaving therapies for severe leukodystrophies. Dan joined us to talk about the challenges …
…
continue reading
"Taking a vaccine from concept and early stage data through to a licensed product that you're putting into millions of people takes 10-15 years on average, but it was done in 10 months. So how did we manage to acheive that? Nobody wanted to be stuck in lockdown forever and so everyone really focused on coming together - a combination of industry, g…
…
continue reading
"Whatever opportunity arises, it may not be on the path that you think you should be on, but it will bring value. You have to do your best to identify what that value is. So keep an open mind about opportunities - there's sometimes value in applying for something that you only have 30% of the requirements for." Orla Cunningham is the Chief Scientif…
…
continue reading
"LinkedIn is like the professional Instagram. It looks like people's careers were so easy, mapped out and planned. It doesn't tell of the difficult decisions, the failures, the challenges, the dead ends and having to start again." Rebecca Godfrey is the Chief Operating Officer of ExpressionEdits and the author of "The Leadership Vaccine". Rebecca t…
…
continue reading
"Cancer drugs only started working once we realised that we actually had to measure what was going on in the tumour and match them appropriately [to patients]...we're just on the cusp of that approach being accepted in neuroscience." Jenny Barnett is the CEO of Monument Therapeutics, a Biotech company using precision medicine approaches to develop …
…
continue reading
"The most important thing is to enjoy what you're doing. If you're in the lab and enjoying your research, that's great. Keep enjoying it and you'll probably delivery well. If you want to keep focusing on research, you can, and if you want to experience different things, you'll have created the opportunity to do so." Paul Thompson is the Chief Scien…
…
continue reading
"Look at oncology 50 years ago. With huge amounts of investment we now think that most form of cancer are treatable. With investment, understanding, time and research that's possible in neurodegeneration - that you can not just slow or even stop but reverse and repair it." Andy Whiting is the CEO of Nevrargenics, a Biotech company spun out of his r…
…
continue reading
"[As a CEO] you have to force yourself to think about what's happening in your business - and that doesn't mean doing 8 hours of Zoom calls a day. Just as it's the gaps between the notes that make music, it's the gaps between the timetable acitvities that enable strategic thinking." Ross Breckenridge is the CEO of Arjuna Therapeutics, a Biotech com…
…
continue reading
"Drug discovery is one of the biggest miracles we can accomplish. You're taking something that didn't exist before, then putting it into the most complex system we know of, hoping that it does one specific thing and not a bunch of other bad things. The fact that it ever works is a miracle." Jonathan Steckbeck is the CEO of Peptilogics, a Biotech co…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Steve Trim, Venomtech
1:03:05
1:03:05
Riproduci in seguito
Riproduci in seguito
Liste
Like
Like aggiunto
1:03:05
"Get experience, talk to people who are doing it, go to networking sessions and interact with business owners - we've all got a story to tell and most are happy to share advice." Steve Trim is the founder and Chief Scientific Officer of Venomtech, a truly unique company that helps Biotech researchers to work with venom-based assays. Steve talked to…
…
continue reading
"Embrace being uncomfortable. It's easy to say, I know, but go out there and don't be afraid. It will be challenging, it will make you anxious but if you don't try, [what you want] won't happen." Tomas Dias is the Chief Technology Officer at Mursla, a Biotech company using extracellular vesicles to develop next-generation liquid biopsy tests in ser…
…
continue reading
"As a PhD, you're very focused on the question and the process of how you get things done. Our focus [as a Biotech company] is on what impact we want to have, where we're going and the key questions that our partners are trying to answer." Samantha Dale Strasser is the Chief Scientific Officer of Pepper Bio, the world's first transomic analysis com…
…
continue reading
"It comes down to [the question], 'Why are you here?'. We looked at this project and thought, if we do this and it works, then we have a therapy that could prevent people from progressing down the inevitable slide into insulin dependence, with all the long term impacts that implies. And that would be a really worthwhile course to take." Nara Dauben…
…
continue reading
"Don't think that just because you've done a Biology or Chemistry degree, this is your path forever....I didn't become an entrepreneur until the age of 42. Your [career] path isn't fixed." Richard Weaver is a consultant to Biotech companies on their drug development programmes, specialising in DMPK. Before becoming a consultant, Rich was the founde…
…
continue reading
"Anybody can be a pair of hands, follow a protocol and do what they're told. If you want more than that, if you want to be a pair of hands with a brain, then you have to think differently." Nuno Madeira do Ó is the CEO of Reflection Therapeutics, a Biotech company harnessing the potential of Tregs to treat inflammatory diseases. Nuno shared the sto…
…
continue reading
"We are in such an exciting time in Life Sciences...if you have an idea, go for it, because there's a lot of VC money out there...and the appetite to invest early has improved, so it's the right time to speak to investors about potential ideas." Leigh Brody is an entrepreneur, executive and now venture investor at AlbionVC, where she oversees the U…
…
continue reading
"Join a young company. If you're employee number 10, you're 10% of the business as opposed to 1% in a 100 person company. You will learn way more just by osmosis....if you're curious and ask questions." Samuel Woodhouse is the VP of Operations at CoSyne Therapeutics, a technology-driven drug discovery company on a mission to reinvent Pharma from th…
…
continue reading
"In the first few years [of your career], what's really important is to establish yourself. You learn a certain skillset in academia...the next thing is to really apply that in the context of a drug discovery project....if you develop a proven track record as a good scientist, good things will happen." Roland Burli is the Vice President of Drug Dis…
…
continue reading